LAUSR

Abstract Multiple extrapulmonary symptoms have been described in individuals with elevated inflammatory markers after COVID infection, which have been grouped and classified as a new inflammatory syndrome, called multisystem inflammatory syndrome in adults (MIS-A). However, little is known about MIS-A, including its prevalence, predisposing conditions, or patient outcomes. We report a case of severe postvaccination symptoms that occurred after administration of the Moderna vaccine in an individual with no prior history of COVID infection. We also review a case series that fulfills the criteria for MIS-A reported in the literature and summarize the characteristics of patients developing MIS-A after COVID-19 vaccination.